Developer docs
API playgroundTry for free, no card

Search company profiles

Grand Pharma

Full company profile

uuid002b8yx

Namestring
Grand Pharma
Websiteurl
grandpatika.hu
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Per the firmographic record, Grand Pharma is a for-profit pharmaceutical company headquartered in Nyíregyháza, Hungary, that specializes in drug retailing and wholesaling. It was founded in 2004 and operates as a private entity with a headcount of 11–50 employees. The company maintains a web presence at grandpatika.hu; other firmographic details such as customer segments, pricing, and product mix are not disclosed in the available data.

The remaining aggregated data blocks describe a substantially different profile — a pharmaceutical operator with reported presence in China (CHN, Asia per source) that received regulatory approval to launch what is described as the world's first approved drug for Demodex Blepharitis, an eyelash/eyelid condition caused by Demodex mites. This profile is inconsistent with the firmographic data (small Hungarian pharmacy, 11–50 staff, drug retail/wholesale focus) and most likely reflects contamination from China Grand Pharmaceutical & Healthcare Holdings, a larger Hong Kong-listed pharmaceutical group that shares the "Grand Pharma" name. No financial details (revenue, funding rounds, ownership structure) are disclosed in any source.

Given the data conflict, the substantive descriptive basis is the firmographic profile: a small, privately held Hungarian pharmaceutical retailer/wholesaler with a single headquarters in Nyíregyháza and limited public information on products, customers, channels, or pricing beyond its core trade description.

Short descriptiontext

Grand Pharma is a privately held Hungarian pharmaceutical company headquartered in Nyíregyháza, founded in 2004, that operates as a drug retailer and wholesaler with 11–50 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNyíregyháza, Hungary
HQ citystring
Nyíregyháza
HQ countrystring
Hungary
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical distribution, drug retailing, drug wholesaling, ophthalmic medications, prescription drugs
Industry2 codes
PRIMARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmacies and Drug Retailers45611
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Retail-Drug Stores And Proprietary Stores5912
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
No data
Cost components3 values
Supply Chain, Operations, Personnel
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Grand Pharma is a pharmaceutical company that sells drugs through retail and wholesale distribution channels. The company has also developed and received regulatory approval for a Demodex Blepharitis eye drug, described as the world's first approved treatment for Demodex blepharitis, with launch authorized in China.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Demodex Blepharitis Eye Drug
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Allergan (now part of AbbVie) operates a leading ophthalmology pharmaceutical portfolio including treatments for ocular surface conditions and is a broad incumbent comparable to Grand Pharma on specialty ophthalmology products.

2Czech Drug Center (Czech Pharma)
TypeRegional player
Description

Czech Drug Center and similar CEE pharma wholesalers operate regional drug distribution networks comparable in business model to Grand Pharma, though focused on Czech/Slovak markets rather than Hungary.

TypeDirect peer
Description

Hungaropharma is one of Hungary's largest pharmaceutical wholesalers, distributing medicines to pharmacies and hospitals nationwide. It is directly comparable to Grand Pharma as a Hungarian drug wholesaler, though it operates at substantially greater scale.

TypeBroad incumbent
Description

Bausch + Lomb is a major global ophthalmology pharmaceutical and medical-device company with established presence across eye-care indications including ocular surface disease. It is a broad incumbent comparable to Grand Pharma on the ophthalmology pharmaceutical axis, though operating at vastly greater scale and breadth.

TypeBroad incumbent
Description

Novartis operates a major ophthalmology pharmaceutical franchise globally, including products for ocular surface conditions. It is a broad incumbent comparable to Grand Pharma on the ophthalmology pharmaceutical category, particularly relevant given the Demodex Blepharitis eye-drug overlap with ocular surface disease.

6Santen Pharmaceutical
TypeEmerging player
Description

Santen is a Japan-headquartered specialty ophthalmology pharmaceutical company with a global footprint including Asia. It is comparable to Grand Pharma on the ophthalmology specialty pharma axis, particularly given the China-focused ophthalmology product in Grand Pharma's portfolio.

TypeDirect peer
Description

PHOENIX Group is a leading European pharmaceutical wholesale and retail pharmacy operator with significant presence in Hungary and CEE. It is directly comparable to Grand Pharma on drug wholesaling and pharmacy retail business model across European geographies.

8China Grand Pharmaceutical and Healthcare Holdings
TypeDirect peer
Description

China Grand Pharmaceutical is a Hong Kong-listed specialty pharmaceutical company that has launched Demodex-related ophthalmology products in China. It is a direct peer on both the ophthalmology specialty pharma product axis and the China commercialization axis referenced in Grand Pharma's source data.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Grand Pharma

Pharmaceuticalsgrandpatika.hu

Grand Pharma is a privately held Hungarian pharmaceutical company headquartered in Nyíregyháza, founded in 2004, that operates as a drug retailer and wholesaler with 11–50 employees.

What Grand Pharma does

Per the firmographic record, Grand Pharma is a for-profit pharmaceutical company headquartered in Nyíregyháza, Hungary, that specializes in drug retailing and wholesaling. It was founded in 2004 and operates as a private entity with a headcount of 11–50 employees. The company maintains a web presence at grandpatika.hu; other firmographic details such as customer segments, pricing, and product mix are not disclosed in the available data.

The remaining aggregated data blocks describe a substantially different profile — a pharmaceutical operator with reported presence in China (CHN, Asia per source) that received regulatory approval to launch what is described as the world's first approved drug for Demodex Blepharitis, an eyelash/eyelid condition caused by Demodex mites. This profile is inconsistent with the firmographic data (small Hungarian pharmacy, 11–50 staff, drug retail/wholesale focus) and most likely reflects contamination from China Grand Pharmaceutical & Healthcare Holdings, a larger Hong Kong-listed pharmaceutical group that shares the "Grand Pharma" name. No financial details (revenue, funding rounds, ownership structure) are disclosed in any source.

Given the data conflict, the substantive descriptive basis is the firmographic profile: a small, privately held Hungarian pharmaceutical retailer/wholesaler with a single headquarters in Nyíregyháza and limited public information on products, customers, channels, or pricing beyond its core trade description.

Grand Pharma firmographics

Firmographics
Name
Grand Pharma
Website
https://grandpatika.hu
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Grand Pharma is a privately held Hungarian pharmaceutical company headquartered in Nyíregyháza, founded in 2004, that operates as a drug retailer and wholesaler with 11–50 employees.
Ownership category
akta.pro rank

Grand Pharma industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmacies and Drug Retailers (45611), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical distribution
  • Drug retailing
  • Drug wholesaling
  • Ophthalmic medications
  • Prescription drugs

Where Grand Pharma is headquartered

Location

Headquarters

HQ city
Nyíregyháza
HQ country
Hungary
HQ region
Europe

Markets served

Grand Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel

Grand Pharma product offering

Product offering

Core offering

Grand Pharma is a pharmaceutical company that sells drugs through retail and wholesale distribution channels. The company has also developed and received regulatory approval for a Demodex Blepharitis eye drug, described as the world's first approved treatment for Demodex blepharitis, with launch authorized in China.

Differentiator

Problem solved

Functional benefit

Products and services

  • Demodex Blepharitis Eye Drug

Companies that use Grand Pharma

Customer profile

Ideal customer profiles1 record

Grand Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Grand Pharma partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights2 records

Grand Pharma competitors and assessment

Company assessment

Broad incumbents

  • Allergan / AbbVie: Allergan (now part of AbbVie) operates a leading ophthalmology pharmaceutical portfolio including treatments for ocular surface conditions and is a broad incumbent comparable to Grand Pharma on specialty ophthalmology products.
  • Bausch + Lomb (Bausch Health): Bausch + Lomb is a major global ophthalmology pharmaceutical and medical-device company with established presence across eye-care indications including ocular surface disease. It is a broad incumbent comparable to Grand Pharma on the ophthalmology pharmaceutical axis, though operating at vastly greater scale and breadth.
  • Novartis (Ophthalmology division): Novartis operates a major ophthalmology pharmaceutical franchise globally, including products for ocular surface conditions. It is a broad incumbent comparable to Grand Pharma on the ophthalmology pharmaceutical category, particularly relevant given the Demodex Blepharitis eye-drug overlap with ocular surface disease.

Regional players

  • Czech Drug Center (Czech Pharma): Czech Drug Center and similar CEE pharma wholesalers operate regional drug distribution networks comparable in business model to Grand Pharma, though focused on Czech/Slovak markets rather than Hungary.

Direct peers

  • Hungaropharma: Hungaropharma is one of Hungary's largest pharmaceutical wholesalers, distributing medicines to pharmacies and hospitals nationwide. It is directly comparable to Grand Pharma as a Hungarian drug wholesaler, though it operates at substantially greater scale.
  • PHOENIX Group: PHOENIX Group is a leading European pharmaceutical wholesale and retail pharmacy operator with significant presence in Hungary and CEE. It is directly comparable to Grand Pharma on drug wholesaling and pharmacy retail business model across European geographies.
  • China Grand Pharmaceutical and Healthcare Holdings: China Grand Pharmaceutical is a Hong Kong-listed specialty pharmaceutical company that has launched Demodex-related ophthalmology products in China. It is a direct peer on both the ophthalmology specialty pharma product axis and the China commercialization axis referenced in Grand Pharma's source data.

Emerging players

  • Santen Pharmaceutical: Santen is a Japan-headquartered specialty ophthalmology pharmaceutical company with a global footprint including Asia. It is comparable to Grand Pharma on the ophthalmology specialty pharma axis, particularly given the China-focused ophthalmology product in Grand Pharma's portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Grand Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Grand Pharma leadership team

Management profile

Number of profiles

Grand Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Grand Pharma M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grand Pharma

What does Grand Pharma do?

Grand Pharma is a pharmaceutical company that sells drugs through retail and wholesale distribution channels. The company has also developed and received regulatory approval for a Demodex Blepharitis eye drug, described as the world's first approved treatment for Demodex blepharitis, with launch authorized in China.

When was Grand Pharma founded?

Grand Pharma was founded in 2004. It employs 11 to 50 people.

Where is Grand Pharma based?

Grand Pharma is headquartered in Nyíregyháza, Hungary, in the Europe region.

Who are Grand Pharma's main competitors?

Broad incumbents on record are Allergan / AbbVie, Bausch + Lomb (Bausch Health) and Novartis (Ophthalmology division). Czech Drug Center (Czech Pharma) is listed as a regional player. Direct peers are Hungaropharma, PHOENIX Group and China Grand Pharmaceutical and Healthcare Holdings. Santen Pharmaceutical is listed as an emerging player.

Does Grand Pharma have an API?

No public API is recorded for Grand Pharma.

What industry is Grand Pharma in?

Grand Pharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies), with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 45611 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales